Please login to the form below

Not currently logged in

Ablynx appoints Robert Zeldin chief medical officer

He previously servedat Merck & Co, Novartis and the FDA

Belgium biopharmaceutical company Ablynx has appointed Dr Robert Zeldin to replace Dr Dominique Tersago as its chief medical officer.

A clinical immunologist, Zeldin has more than 15 years combined regulatory and industry experience, having previously served at Merck & Co, Novartis and the FDA.

He has held senior level clinical development positions within pharma and prior to his move into the industry, Zeldin spent several years in private practice and two years as a medical officer at the FDA's Center for Biologics Evaluation and Research.

Ablynx CEO Dr Edwin Moses said: “We are very pleased that someone with Robert's track record and experience is joining Ablynx as chief medical officer.

“Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders.”

3rd December 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...